Potential remedy for the 'mental fog' in cancer patients

Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University (WVU), researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce. The WVU researchers' study has just been published in the September issue of the Springer journal Metabolic Brain Disease.

Rats were given the commonly used chemotherapy drugs adriamycin and cyclophosphamide. When on the drugs, rats who were trained to prefer a light room to a dark room forgot their training.

"When animals are treated with chemotherapy drugs, they lose memory," said Gregory Konat, Ph.D., professor of neurobiology and anatomy at WVU. "When we add NAC during treatment, they don't lose memory."

Chosen for its antioxidant properties, NAC is a modified form of the dietary amino acid cysteine.

Jame Abraham, M.D., director of the Comprehensive Breast Cancer Program at WVU's Mary Babb Randolph Cancer Center, said as "chemobrain" entered the national lexicon, many patients expressed frustration about doctors not taking the complaints seriously.

"In the past, there was a lot of ignorance among doctors about chemo-induced cognitive problems," Dr. Abraham said. "In some patients, problems can persist for up to two years."

The WVU authors say as many as 40 percent of cancer patients undergoing chemotherapy complain of symptoms such as severe memory and attention deficits. Previously, scientists suspected the cancer, rather than chemo drugs, might be the cause.

Earlier this year, Dr. Abraham's team of researchers used MRI scans to document the extent of changes to the brain in women who received chemotherapy for breast cancer. Now the connection between drugs and memory loss is clear, and a potential remedy is suggested as well.

"At this point, we have no evidence to say that NAC is safe in patients who are getting chemotherapy," Abraham said. "We need more studies to confirm the role of NAC in patients."

Source: Springer

Related stories:

Mapping brain cancer to find best treatment
There's never a good time to have brain cancer. Still, Karl DuBose tries to look on the bright side. "It's weird to say, but today - and here in Seattle - might be the best time and place to get this disease," said the 45-year-old Everett, Wash., man, who was slammed with the diagnosis last summer.
Genomic signature of colon cancer may individualize treatment
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.
Iressa proves just as effective as chemotherapy for lung cancer
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.
Study identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
Scientists find cell pathway driving a deadly sub-type of breast cancer
An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women.
Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Battling bacteria in the blood: Researchers tackle deadly infections
It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it.
Researchers aim to over-stress already taxed mantle cell lymphoma cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.

News discussion:

Medicine & Health news